Skip to main content
SpringerLink
Log in

A meta-analysis on the association between PPAR-γ Pro12Ala polymorphism and polycystic ovary syndrome

  • Genetics
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To investigate the influence of the peroxisome proliferator activated receptor gamma (PPAR-γ) Pro12Ala polymorphism on the susceptibility of polycystic ovary syndrome (PCOS) and body mass index (BMI), fast insulin levels, homeostasis model assessment of insulin resistance (HOMA-IR) in PCOS patients.

Methods

PubMed, EMBASE, MEDLINE and CENTRAL databases were searched to identify eligible studies. We then conducted a meta-analysis to examine the association between Pro12Ala polymorphism and PCOS.

Results

Seventeen eligible studies, including 2,149 patients and 2,124 controls were enrolled in this meta-analysis. Pro12Ala polymorphism was significantly associated with the susceptibility of PCOS (odds ratio [OR] 0.74, 95 % confidence interval [CI] [0.61, 0.90] for allele; OR 0.70, 95 % CI [0.57, 0.86] for genotype). In the European subgroup of PCOS, the X/Ala genotype was associated with lower BMI (mean difference [MD] −1.08, 95 % CI [−2.08, −0.09]) and fast insulin levels (MD −19.82, 95 % CI [−34.07, −5.58]). However, this polymorphism did not display an impact on HOMA-IR in PCOS patients.

Conclusions

Ala variant would decrease the risk of PCOS and result in lower BMI and fast insulin levels in a European population, but had no impact on HOMA-IR in PCOS patients. Further studies are required to elucidate these associations more clear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671–83.

    Article  PubMed  Google Scholar 

  2. Hart R, Norman R. Polycystic ovarian syndrome–prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol. 2006;20:751–78.

    Article  PubMed  Google Scholar 

  3. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond). 2008;32:1035–41.

    Article  CAS  Google Scholar 

  4. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–61.

    Article  PubMed  CAS  Google Scholar 

  5. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36.

    Article  PubMed  CAS  Google Scholar 

  6. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278–85. discussion 86–90.

    Article  PubMed  CAS  Google Scholar 

  7. Legro RS, Driscoll D, Strauss 3rd JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95:14956–60.

    Article  PubMed  CAS  Google Scholar 

  8. Battaglia C, Regnani G, Mancini F, Iughetti L, Flamigni C, Venturoli S. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients. A pilot study. Hum Reprod. 2002;17:771–6.

    Article  PubMed  Google Scholar 

  9. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91:2100–4.

    Article  PubMed  CAS  Google Scholar 

  10. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 1999;42:1033–49.

    Article  PubMed  CAS  Google Scholar 

  11. Jansen E, Laven JS, Dommerholt HB, Polman J, van Rijt C, van den Hurk C, et al. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol. 2004;18:3050–63.

    Article  PubMed  CAS  Google Scholar 

  12. Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function–implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol. 2005;3:41.

    Article  PubMed  Google Scholar 

  13. Lovekamp-Swan T, Chaffin CL. The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Mol Cell Endocrinol. 2005;233:15–24.

    Article  PubMed  CAS  Google Scholar 

  14. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol. 2006;189:199–209.

    Article  PubMed  CAS  Google Scholar 

  15. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration: 2009. Available from http://www.cochrane-handbook.org.

  16. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.

    PubMed  CAS  Google Scholar 

  17. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat med. 2002;21:1539–58.

    Article  PubMed  Google Scholar 

  18. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002;87:772–5.

    Article  PubMed  CAS  Google Scholar 

  19. Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, et al. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod. 2003;18:540–3.

    Article  PubMed  CAS  Google Scholar 

  20. Orio Jr F, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V, et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:5887–92.

    Article  PubMed  CAS  Google Scholar 

  21. San-Millán JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004;89:2640–6.

    Article  PubMed  Google Scholar 

  22. Orio Jr F, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5110–5.

    Article  PubMed  CAS  Google Scholar 

  23. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod. 2005;20:1590–5.

    Article  PubMed  CAS  Google Scholar 

  24. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2005;62:573–9.

    Article  CAS  Google Scholar 

  25. Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113:275–81.

    Article  PubMed  CAS  Google Scholar 

  26. Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Yetkin I, Ayvaz G, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:206–10.

    Article  PubMed  CAS  Google Scholar 

  27. Wang Y, Wu X, Cao Y, Yi L, Fan H, Chen J. Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril. 2006;85:1536–40.

    Article  PubMed  CAS  Google Scholar 

  28. Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:336–42.

    Article  PubMed  Google Scholar 

  29. Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril. 2007;87:862–9.

    Article  PubMed  CAS  Google Scholar 

  30. Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, et al. Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes. 2008;116:481–6.

    Article  PubMed  CAS  Google Scholar 

  31. Koika V, Marioli DJ, Saltamavros AD, Vervita V, Koufogiannis KD, Adonakis G, et al. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161:317–22.

    Article  PubMed  CAS  Google Scholar 

  32. Gu BH, Baek KH. Pro12Ala and His447His polymorphisms of PPAR-gamma are associated with polycystic ovary syndrome. Reprod Biomed Online. 2009;18:644–50.

    Article  PubMed  CAS  Google Scholar 

  33. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens). 2009;8:267–72.

    Google Scholar 

  34. San-Millán JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case–control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf). 2010;72:383–92.

    Article  Google Scholar 

  35. Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY. Peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha gene polymorphisms in Korean women with polycystic ovary syndrome. Gynecol Obstet Invest. 2010;70:1–7.

    Article  PubMed  CAS  Google Scholar 

  36. Christopoulos P, Mastorakos G, Gazouli M, Deligeoroglou E, Katsikis I, Diamanti-Kandarakis E, et al. Peroxisome proliferator-activated receptor-gamma and -delta polymorphisms in women with polycystic ovary syndrome. Ann N Y Acad Sci. 2010;1205:185–91.

    Article  PubMed  CAS  Google Scholar 

  37. Bidzińska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, Slezak R, Bednarek-Tupikowska G, Milewicz A, et al. Pro12Ala PPAR gamma2 gene polymorphism in women with polycystic ovary syndrome. Ginekol Pol. 2011;82:426–9.

    PubMed  Google Scholar 

  38. Bidzińska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, Slezak R, Bednarek-Tupikowska G, Milewicz A. Pro12Ala PPAR gamma2 gene polymorphism in PCOS women: the role of compounds regulating satiety. Gynecol Endocrinol. 2012;28:195–8.

    Article  PubMed  Google Scholar 

  39. Dragojevič J, Marc J, Mlinar B. Association between Pro12Ala and His477His polymorphisms in PPARG gene and insulin resistance in patients with polycystic ovary syndrome. Biochemia Medica. 2008;18:342–50.

    Google Scholar 

  40. Nardo LG, Patchava S, Laing I. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med. 2008;50:267–78.

    PubMed  CAS  Google Scholar 

  41. Tőnjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care. 2006;29:2489–97.

    Article  PubMed  Google Scholar 

  42. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet. 2003;40:773–80.

    Article  PubMed  CAS  Google Scholar 

  43. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284–7.

    Article  PubMed  CAS  Google Scholar 

  44. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57:343–50.

    Article  CAS  Google Scholar 

  45. Palep-Singh M, Picton HM, Vrotsou K, Maruthini D, Balen AH. South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. Eur J Obstet Gynecol Reprod Biol. 2007;134:202–7.

    Article  PubMed  CAS  Google Scholar 

  46. Palep-Singh M, Picton HM, Yates ZR, Barth J, Balen AH. Polycystic ovary syndrome and the single nucleotide polymorphisms of methylenetetrahydrofolate reductase: a pilot observational study. Hum Fertil (Camb). 2007;10:33–41.

    Article  CAS  Google Scholar 

  47. Glintborg D, Mumm H, Hougaard D, Ravn P, Andersen M. Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. Clin Endocrinol (Oxf). 2010;73:732–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank the authors of the original studies who responded to request for data.

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Urology, Children’s Hospital of Chongqing Medical University, 136 Zhongshan 2nd Road, Yuzhong District, Chongqing, 400014, People’s Republic of China

    Junli He, Junhong Liu, Feng Liu & Xuliang Li

  2. Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    Junli He, Junhong Liu, Feng Liu & Xuliang Li

  3. Key Laboratory of Pediatrics in Chongqing, CSTC2009CA5002, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    Junli He, Junhong Liu, Feng Liu & Xuliang Li

  4. Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    Junli He, Junhong Liu, Feng Liu & Xuliang Li

  5. Neonatal Diagnosis and Treatment Center, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    Li Wang

Authors
  1. Junli He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junhong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xuliang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuliang Li.

Additional information

Capsule

This meta-analysis indicated that Ala variant would decrease the risk of PCOS; X/Ala genotype lowered BMI and fast insulin levels, but had no impact on HOMA-IR in PCOS patients.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, J., Wang, L., Liu, J. et al. A meta-analysis on the association between PPAR-γ Pro12Ala polymorphism and polycystic ovary syndrome. J Assist Reprod Genet 29, 669–677 (2012). https://doi.org/10.1007/s10815-012-9772-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-012-9772-4

Keywords

Search

Navigation